Clinical Trials Logo

Peanut Hypersensitivity clinical trials

View clinical trials related to Peanut Hypersensitivity.

Filter by:

NCT ID: NCT06331728 Not yet recruiting - Peanut Allergy Clinical Trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

Start date: July 2024
Phase: Phase 1
Study type: Interventional

The goal of this randomized, double-blind, placebo-controlled, single ascending dose clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IGNX001 in peanut-allergic adults and older Adolescents.

NCT ID: NCT06297083 Recruiting - Peanut Allergy Clinical Trials

Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy

HILO
Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This study will compare the effectiveness of three different treatments to treat peanut allergy

NCT ID: NCT06260956 Not yet recruiting - Clinical trials for Food Allergy in Infants

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

ESCAPE
Start date: September 2024
Phase: N/A
Study type: Interventional

Peanut allergy is the most common cause of fatal and near-fatal food-allergic reactions and egg allergy is among the two most common causes of food-induced anaphylaxis. The proposed research will explore the development of sensitization to these food(s) in infants based on maternal consumption or avoidance during pregnancy and breastfeeding.

NCT ID: NCT06256146 Recruiting - Peanut Allergy Clinical Trials

Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety

IMPROVES
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Protocols for Oral Immunotherapy (OIT) for the main food allergens have been recently incorporated in clinical practice for food allergies and their clinical benefits have been acknowledged in European and Canadian official guidelines. There has been some reluctance in both clinicians and patients to implement these therapies, primarily because of the risk of allergic reactions during the desensitization process. This study will investigate if protocols using low doses of a food allergen or processed versions of the allergen can be both effective in conferring desensitization while inducing fewer allergic symptoms during the desensitization process.

NCT ID: NCT06192914 Recruiting - Allergy Clinical Trials

EPAP, Interviewstudy

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to learn about repetitive anaphylactic reactions in food allergic patients and to compare the frequency of repetitive reactions between different elicitors in food allergic patients. The main question it aims to answer are: • Is there an elicitor specific difference in the occurrence of anaphylactic reactions once the elicitor has been identified and the patient received counselling about its avoidance? Participants will answer questionnaires via a link they will receive via e-mail at baseline and 3, 6, 12 and 24 months after inclusion in the study.

NCT ID: NCT05741476 Recruiting - Allergy, Peanut Clinical Trials

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

VITESSE
Start date: February 21, 2023
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.

NCT ID: NCT05695261 Recruiting - Food Allergy Clinical Trials

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Start date: June 8, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II randomized double-blind placebo-controlled trial that aims at evaluating the safety and tolerability of oral encapsulated fecal microbial transplantation therapy (MTT) in peanut allergic patients. In this research the investigators would like to learn more about ways to treat peanut allergies. The primary objective is to evaluate whether MTT with antibiotic pretreatment can increase the threshold of peanut reactivity during a double-blind placebo-controlled food challenge from <=100 mg peanut protein to 300 mg after 28 days of MTT /placebo therapy and 4 months post therapy initiation.

NCT ID: NCT05667610 Recruiting - Peanut Allergy Clinical Trials

Immune-supportive Diet and Gut Permeability in Allergic Children

DIAMETER
Start date: September 8, 2022
Phase: N/A
Study type: Interventional

Peanut and nut allergy can be life threatening. Some patients have very low threshold levels (i.e. the amounts of peanut and nuts to which the patients react), others react to higher doses. The reasons for these differences in threshold are not well understood. Patients with peanut and nut allergy often suffer from other allergic diseases (atopic dermatitis, hay fever and asthma). A disturbed gut microbiota composition and an increased gut permeability may explain the development of allergic disease. We hypothesize that increased gut permeability is related to low threshold levels to peanuts or nuts. In addition, as it is known that nutrition can influence our gut permeability, we also hypothesize that a healthful immune-supportive diet restores gut permeability and alleviates symptoms. Therefore, the purpose of the study is to study in peanut and nut allergic children: 1. the relationship between gut permeability and threshold levels to peanut or nuts; 2. the effect of an immune-supportive diet on gut permeability, gut microbiome composition, coexisting allergic symptoms and quality of life

NCT ID: NCT05662800 Recruiting - Atopic Dermatitis Clinical Trials

Development of Peanut, Sesame, and Tree Nut Allergy in Polish Children at High Risk of Food Allergy

Start date: April 17, 2023
Phase:
Study type: Observational

The aim of the study is to assess the prevalence of peanut, tree nuts, and sesame allergy in Polish children at high risk of food allergy. Additionally, the timing of the development of peanut, tree nuts and sesame allergy in the first three years of life in a high-risk population will be assessed.

NCT ID: NCT05621317 Recruiting - Clinical trials for Immune System Diseases

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Start date: February 9, 2023
Phase: Phase 2
Study type: Interventional

The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.